WO2008073856A3 - Delivery of nanoparticles and/or agents to cells - Google Patents

Delivery of nanoparticles and/or agents to cells Download PDF

Info

Publication number
WO2008073856A3
WO2008073856A3 PCT/US2007/086880 US2007086880W WO2008073856A3 WO 2008073856 A3 WO2008073856 A3 WO 2008073856A3 US 2007086880 W US2007086880 W US 2007086880W WO 2008073856 A3 WO2008073856 A3 WO 2008073856A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
nanoparticles
agents
cells
delivery
Prior art date
Application number
PCT/US2007/086880
Other languages
French (fr)
Other versions
WO2008073856A2 (en
Inventor
Sangeeta N Bhatia
Todd Harris
Amit Agarwal
Dal-Hee Min
Austin M Derfus
Maltzahn Geoffrey Von
Original Assignee
Massachusetts Inst Technology
Univ California San Diego
Sangeeta N Bhatia
Todd Harris
Amit Agarwal
Dal-Hee Min
Austin M Derfus
Maltzahn Geoffrey Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Univ California San Diego, Sangeeta N Bhatia, Todd Harris, Amit Agarwal, Dal-Hee Min, Austin M Derfus, Maltzahn Geoffrey Von filed Critical Massachusetts Inst Technology
Priority to AU2007333225A priority Critical patent/AU2007333225B2/en
Priority to EP07869062A priority patent/EP2099496A2/en
Priority to CA002671850A priority patent/CA2671850A1/en
Publication of WO2008073856A2 publication Critical patent/WO2008073856A2/en
Publication of WO2008073856A3 publication Critical patent/WO2008073856A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals

Abstract

The present invention provides systems, methods, and compositions for targeted delivery of nanoparticles and/or agents to tissues, cells, and/or subcellular locales. In general, compositions comprise a nanoparticle (e.g. quantum dot, polymeric particle, etc.), at least one modulating entity (such as a targeting moiety, transfection reagent, protective entity, etc.), and at least one agent to be delivered (e.g. therapeutic, prophylactic, and/or diagnostic agent). The present invention provides methods of making and using nanoparticle entities in accordance with the present invention.
PCT/US2007/086880 2006-12-08 2007-12-07 Delivery of nanoparticles and/or agents to cells WO2008073856A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2007333225A AU2007333225B2 (en) 2006-12-08 2007-12-07 Delivery of nanoparticles and/or agents to cells
EP07869062A EP2099496A2 (en) 2006-12-08 2007-12-07 Delivery of nanoparticles and/or agents to cells
CA002671850A CA2671850A1 (en) 2006-12-08 2007-12-07 Delivery of nanoparticles and/or agents to cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87389706P 2006-12-08 2006-12-08
US60/873,897 2006-12-08
US96938907P 2007-08-31 2007-08-31
US60/969,389 2007-08-31

Publications (2)

Publication Number Publication Date
WO2008073856A2 WO2008073856A2 (en) 2008-06-19
WO2008073856A3 true WO2008073856A3 (en) 2009-05-07

Family

ID=39421253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086880 WO2008073856A2 (en) 2006-12-08 2007-12-07 Delivery of nanoparticles and/or agents to cells

Country Status (5)

Country Link
US (2) US20080213377A1 (en)
EP (1) EP2099496A2 (en)
AU (1) AU2007333225B2 (en)
CA (1) CA2671850A1 (en)
WO (1) WO2008073856A2 (en)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
EP2530168B1 (en) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Microfluidic Devices
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP2009545407A (en) 2006-08-02 2009-12-24 ボストン サイエンティフィック サイムド，インコーポレイテッド End prosthesis with 3D decomposition control
DE602007011114D1 (en) 2006-09-15 2011-01-20 Boston Scient Scimed Inc BIODEGRADABLE ENDOPROTHESIS WITH BIOSTABILES INORGANIC LAYERS
WO2008034066A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
JP2010503489A (en) 2006-09-15 2010-02-04 ボストン サイエンティフィック リミテッド Biodegradable endoprosthesis and method for producing the same
WO2008034013A2 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
US7615385B2 (en) 2006-09-20 2009-11-10 Hypres, Inc Double-masking technique for increasing fabrication yield in superconducting electronics
WO2008136869A2 (en) * 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
ES2506144T3 (en) 2006-12-28 2014-10-13 Boston Scientific Limited Bioerodible endoprosthesis and their manufacturing procedure
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2008156460A1 (en) * 2007-06-21 2008-12-24 The Boeing Company Bioconjugated nanoparticles
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US20090271347A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US9560967B2 (en) 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9449150B2 (en) 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US9662391B2 (en) 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US20090287301A1 (en) * 2008-05-16 2009-11-19 Boston Scientific, Scimed Inc. Coating for medical implants
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
DE112009001284A5 (en) * 2008-06-27 2011-06-30 Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG, 70839 composite
JP2011526619A (en) 2008-06-30 2011-10-13 サイレンシード リミテッド Topical drug delivery system, method and composition thereof
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8202544B2 (en) * 2008-09-18 2012-06-19 Carestream Health, Inc. High capacity non-viral vectors
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2010078569A2 (en) * 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
WO2010099463A2 (en) * 2009-02-27 2010-09-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Joint bioscaffolds
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
EP2403546A2 (en) 2009-03-02 2012-01-11 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8673267B2 (en) 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
EP2411402B1 (en) 2009-03-23 2014-02-12 Yeditepe Universitesi Synthesis of oligonucleotide mediated gold core- silver shell nanoparticles
EP2432460B1 (en) * 2009-05-21 2015-04-22 Institute Of Life Sciences Water dispersible glyceryl monooleate magnetic nanoparticle formulation
AU2010254549B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
EP3499233A3 (en) * 2009-07-02 2019-09-18 Sloan-Kettering Institute for Cancer Research Fluorescent silica-based nanoparticles
US9999694B2 (en) 2009-07-02 2018-06-19 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
RU2541820C2 (en) * 2009-09-14 2015-02-20 Конинклейке Филипс Электроникс Н.В. Device and method for active substance displacement and activation
WO2011042564A1 (en) * 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP4089169A1 (en) 2009-10-12 2022-11-16 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US8565892B2 (en) 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
US10194825B2 (en) * 2009-11-06 2019-02-05 Imagion Biosystems Inc. Methods and apparatuses for the localization and treatment of disease such as cancer
US20110111002A1 (en) * 2009-11-12 2011-05-12 Calin Viorel Pop Transport and delivery of glutathione into human cells using gold nanoparticles
US20120307962A1 (en) * 2009-12-16 2012-12-06 Georgia Tech Resarch Corporation Systems and methods for x-ray fluorescence computed tomography imaging with nanoparticles
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
US9180161B2 (en) * 2010-02-26 2015-11-10 Sanford Burnham Prebys Medical Discovery Institute CAR peptide for homing, diagnosis and targeted therapy for pulmonary and fibrotic disorders
CN102858153A (en) * 2010-03-12 2013-01-02 加利福尼亚大学董事会 Triggered cargo release from nanoparticle stabilized liposomes
US8461300B2 (en) * 2010-03-22 2013-06-11 Sandia Corporation Materials and methods for stabilizing nanoparticles in salt solutions
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
EP2372347A1 (en) * 2010-03-26 2011-10-05 Institut Pasteur Method to increase the number of detectable photons during the imaging of a biological marker
WO2011123069A1 (en) * 2010-03-31 2011-10-06 Agency For Science, Technology And Research Conjugate of magnetic particle and surface modifier linked through cleavable peptide bond
US8790621B2 (en) 2010-04-12 2014-07-29 Iowa State University Research Foundation, Inc. Nanoparticles and nanoparticle compositions
US20130289520A1 (en) * 2010-04-23 2013-10-31 Children's Hospital Boston Targeted and light-activated cytosolic drug delivery
US20120009130A1 (en) * 2010-05-06 2012-01-12 Nanoaxis Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques
US8557329B2 (en) 2010-05-06 2013-10-15 International Business Machines Corporation Method for silica encapsulation of magnetic particles
MX2012013713A (en) 2010-05-26 2013-01-28 Selecta Biosciences Inc Nanocarrier compositions with uncoupled adjuvant.
US20140086828A1 (en) * 2010-05-28 2014-03-27 Aaron E. Foster Modified gold nanoparticles for therapy
US20130090545A1 (en) * 2010-06-08 2013-04-11 Edward R. Flynn Methods and apparatuses for the localization and treatment of cancer
US20130184835A1 (en) 2010-07-09 2013-07-18 Board Of Regents Of The Unversity Of Texas System Biodegradable scaffolds
AU2011293269B2 (en) * 2010-08-27 2015-10-01 The Board Of Trustees Of The Leland Stanford Junior University Microscopy imaging device with advanced imaging properties
US20120089009A1 (en) * 2010-10-11 2012-04-12 Omary Reed A Methods and apparatus to deliver nanoparticles to tissue using electronanotherapy
CA2816121C (en) 2010-11-01 2017-06-13 Syracuse University System and method for delivery of dna-binding chemotherapy drugs using nanoparticles
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
CA2811113A1 (en) 2010-11-09 2012-05-18 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use thereof
US10363309B2 (en) * 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
AU2012229103A1 (en) 2011-03-15 2013-10-31 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
CN103533922A (en) * 2011-04-22 2014-01-22 英特维特国际股份有限公司 Antigenic formulation
AU2012249474A1 (en) 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
WO2012155021A1 (en) * 2011-05-11 2012-11-15 Nanovalent Pharmaceuticals, Inc. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor
WO2012155920A1 (en) * 2011-05-16 2012-11-22 Danmarks Tekniske Universitet Charge triggering of self-organized nanoparticles
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
WO2013009690A2 (en) 2011-07-09 2013-01-17 The Regents Of The University Of California Leukemia stem cell targeting ligands and methods of use
US9532949B2 (en) 2011-07-19 2017-01-03 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EA201490381A1 (en) 2011-07-29 2014-06-30 Селекта Байосайенсиз, Инк. SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL)
US20130040953A1 (en) * 2011-08-10 2013-02-14 Amy S. Paller Promotion of wound healing
WO2013033717A1 (en) * 2011-09-02 2013-03-07 The Regents Of The University Of California Enzyme responsive nanocapsules for protein delivery
WO2013036827A2 (en) 2011-09-08 2013-03-14 The Regents Of The University Of California Fungal-specific metalloproteases and uses thereof
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
BR112014009753B1 (en) * 2011-10-21 2020-09-15 Stemgenics, Inc BIOCOMPATIBLE NANOPARTICLE FUNCTIONED AND RESPECTIVE USE
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
WO2013082304A1 (en) * 2011-11-29 2013-06-06 The Regents Of The University Of California Photonic nanoantenna mediated gene circuit reconfiguration
KR20130084091A (en) 2012-01-16 2013-07-24 삼성전자주식회사 Image forming apparatus
US20130261444A1 (en) * 2012-03-28 2013-10-03 The Uab Research Foundation Photothermal nanostructures in tumor therapy
US20130302252A1 (en) * 2012-05-11 2013-11-14 University Of Washington Through Its Center For Commercialization Polyarginine-coated magnetic nanovector and methods of use thereof
KR101445265B1 (en) * 2012-09-18 2014-09-30 포항공과대학교 산학협력단 Hyaluronic acid-nucleic acid conjugate and composition for nucleic acid delivery containing the same
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
CN104769112A (en) 2012-11-01 2015-07-08 菲克特生物科学股份有限公司 Methods and products for expressing proteins in cells
EP2928453B1 (en) * 2012-12-05 2017-08-02 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Recognition-release nanoporous substrate comprising active agents, methods of their preparation and uses
US9849193B2 (en) * 2013-02-08 2017-12-26 University Of Louisville Research Foundation, Inc. Nanoparticles for drug delivery
WO2014123543A2 (en) * 2013-02-11 2014-08-14 Convoy Therapeutics Skin permeating and cell entering (space) peptides and methods of use therefor
CA2914754A1 (en) 2013-06-07 2014-12-11 Massachusetts Institute Of Technology Affinity-based detection of ligand-encoded synthetic biomarkers
WO2015088977A1 (en) 2013-12-10 2015-06-18 Emory University Targeted protease compositions and uses related thereto
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
TW201525088A (en) * 2013-12-20 2015-07-01 Sicpa Holding Sa Thermoluminescent composite particle and marking comprising same
TN2016000232A1 (en) * 2013-12-23 2017-10-06 Invent Center Kft Iron (iii) oxide containing soil-binding composition.
RU2016127260A (en) 2013-12-31 2018-02-06 Мемориал Слоун Кеттеринг Кэнсэ Сентр SYSTEMS, METHODS AND DEVICE FOR MULTI-CHANNEL DISPLAY OF FLUORESCENT SOURCES IN REAL TIME
FI3690056T3 (en) 2014-01-31 2023-03-19 Factor Bioscience Inc Methods and products for nucleic acid production and delivery
ES2733098T3 (en) * 2014-05-06 2019-11-27 Memorial Sloan Kettering Cancer Center Magnetoenzymatic carrier system for selective imaging and transport and release of active agents
CA3201974A1 (en) 2014-05-29 2015-12-03 Memorial Sloan Kettering Cancer Center Nanoparticle drug conjugates
US9874554B1 (en) 2014-07-16 2018-01-23 Verily Life Sciences Llc Aptamer-based in vivo diagnostic system
WO2016025922A1 (en) * 2014-08-14 2016-02-18 Dana-Farber Cancer Institute, Inc. Coated particles for drug delivery
CA2958292A1 (en) * 2014-08-19 2016-02-25 President And Fellows Of Harvard College Rna-guided systems for probing and mapping of nucleic acids
AU2016218977C1 (en) 2015-02-13 2023-03-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
PL3259598T3 (en) 2015-02-19 2021-03-08 Actorius Innovations And Research Pvt. Ltd. Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
KR101781976B1 (en) * 2015-04-08 2017-10-23 한국과학기술연구원 Nano-structured hybrid particle, manufacturing method thereof, and device containing the particle
CN108377643B (en) 2015-05-29 2021-09-21 纪念斯隆凯特琳癌症中心 Therapeutic methods for inducing nutrient deprivation of cancer cells by iron death using ultra-small nanoparticles
WO2017082985A2 (en) 2015-08-20 2017-05-18 Northeaslem University Zero power plasmonic microelectromechanical device
GB2544481B (en) * 2015-11-16 2019-12-11 Century International Enterprises Ltd A wearable article and a method for producing a wearable article
US11235066B2 (en) * 2015-12-02 2022-02-01 The Regents Of The University Of Michigan Micelles and methods
EP3847965A1 (en) 2015-12-11 2021-07-14 Babson Diagnostics, Inc. Specimen container and method for separating serum or plasma from whole blood
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
AU2017258415B2 (en) * 2016-04-29 2023-03-30 Cornell University Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
CA3022928A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
US20200181649A1 (en) * 2016-07-14 2020-06-11 University Of Delaware Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery
CN106290303B (en) * 2016-08-11 2018-09-04 扬州大学 A kind of multicomponent Raman spectrum method for detecting surface reinforcement based on composite photonic crystal microballoon
CN116115629A (en) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 Nucleic acid products and methods of administration thereof
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
AU2018248327A1 (en) 2017-04-07 2019-10-17 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
US11559591B2 (en) 2017-05-25 2023-01-24 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
CN110554018A (en) * 2018-05-31 2019-12-10 上海市刑事科学技术研究院 Surface enhanced Raman material for detecting 4-bromomethcathinone in aqueous solution and preparation method thereof
US20210332360A1 (en) * 2018-06-04 2021-10-28 Chan Zuckerberg Biohub, Inc. Compositions and methods involving non-natural aptamer libraries
WO2020010133A1 (en) * 2018-07-03 2020-01-09 Rutgers, The State University Of New Jersey A luminescent layered composition and a method for using the composition
WO2020081817A1 (en) * 2018-10-17 2020-04-23 University Of Florida Research Foundation Magnetically responsive composite microparticles for triggered delivery of biologically active agents
CN109133074A (en) * 2018-10-25 2019-01-04 西北工业大学 Preparation method with the difunctional mesopore silicon dioxide nano material of fluorescence imaging and load medicine
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4044926A4 (en) * 2019-10-14 2023-11-15 Actorius Innovations and Research Co. Non-hemolytic compositions and methods of use for recovering disease causing toxic constituents in the blood
CN111554501A (en) * 2020-04-28 2020-08-18 天津大学 Preparation method of superparamagnetic nickel nanoparticles for magnetically adsorbing bacteria and spores
WO2022031700A1 (en) * 2020-08-03 2022-02-10 The Regents Of The University Of California Laser-actuated supercritical injector
CN113045682B (en) * 2021-03-11 2022-06-21 内蒙古大学 Cationic polysaccharide and preparation method and application thereof
WO2023133546A2 (en) * 2022-01-10 2023-07-13 Arizona Board Of Regents On Behalf Of Arizona State University Folding mrna into a nanoscale delivery vehicle
WO2023183872A1 (en) * 2022-03-23 2023-09-28 You First Services, Inc. Delmopinol and delmopinol salt containing nanoparticles and uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013570A2 (en) * 1991-02-12 1992-08-20 Boehringer Ingelheim International Gmbh Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis
US5792645A (en) * 1989-03-16 1998-08-11 Boehringer Ingelheim International Gmbh Protein-polycation nucleic acid complexes and methods of use
WO2001076633A2 (en) * 2000-04-05 2001-10-18 Qiagen Gmbh Targeted transfection of cells using a biotinylated dendrimer
WO2004108165A2 (en) * 2003-06-09 2004-12-16 Consejo Superior De Investigaciones Cientificas Magnetic nanoparticles linked to a lingand
WO2005116226A2 (en) * 2004-05-24 2005-12-08 Midatech Ltd Nanoparticles comprising rna ligands
WO2006017476A2 (en) * 2004-08-02 2006-02-16 The Research Foundation Of State University Of New York Amino functionalized ormosil nanoparticles as delivery vehicles
US20060105052A1 (en) * 2004-11-15 2006-05-18 Acar Havva Y Cationic nanoparticle having an inorganic core
WO2007067733A2 (en) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
CN101180400A (en) * 2004-05-24 2008-05-14 Mida科技有限公司 Nanoparticles comprising rna ligands
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) * 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) * 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
FR2625782B1 (en) * 1988-01-13 1992-04-10 Valeo CONCENTRIC TORSION SHOCK ABSORBER, PARTICULARLY FOR MOTOR VEHICLES
US4940760A (en) * 1988-02-16 1990-07-10 E. I. Du Pont De Nemours And Company Group Transfer Polymerization process employing supported initiators
US5339163A (en) * 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (en) * 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6399754B1 (en) * 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5190521A (en) * 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) * 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) * 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DK204791D0 (en) * 1991-12-20 1991-12-20 Novo Nordisk As UNKNOWN PHARMACEUTICAL PREPARATION
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) * 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) * 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1994021240A2 (en) * 1993-03-17 1994-09-29 Silica Gel Ges.M.B.H Superparamagnetic particles, process for producing the same and their use
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5776748A (en) * 1993-10-04 1998-07-07 President And Fellows Of Harvard College Method of formation of microstamped patterns on plates for adhesion of cells and other biological materials, devices and uses therefor
WO1995024176A1 (en) * 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) * 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
NO180167C (en) * 1994-09-08 1997-02-26 Photocure As Photochemical method for introducing molecules into the cytosol of cells
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5660742A (en) * 1995-03-31 1997-08-26 Joyal Products, Inc. Insulated wire termination, method, and machine
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6582921B2 (en) * 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6127533A (en) * 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US20050037397A1 (en) * 2001-03-28 2005-02-17 Nanosphere, Inc. Bio-barcode based detection of target analytes
US6322901B1 (en) * 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) * 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) * 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19827164A1 (en) * 1998-06-18 1999-12-23 Merck Patent Gmbh Catalytic titanium (IV) oxide mediated geminal symmetrical dialkylation of carboxamides
US6251303B1 (en) * 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6306610B1 (en) * 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6426513B1 (en) * 1998-09-18 2002-07-30 Massachusetts Institute Of Technology Water-soluble thiol-capped nanocrystals
US6403779B1 (en) * 1999-01-08 2002-06-11 Isis Pharmaceuticals, Inc. Regioselective synthesis of 2′-O-modified nucleosides
US6306933B1 (en) * 1999-03-30 2001-10-23 Union Carbide Chemicals & Plastics Technology Corporation Cellulose ether slurries
JP2003507438A (en) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド Enhanced delivery of drugs across and into epithelial tissue using oligoarginine moieties
US7413536B1 (en) * 1999-09-14 2008-08-19 Xenoport, Inc. Substrates and screening methods for transport proteins
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ATE450621T2 (en) * 2000-03-30 2009-12-15 Whitehead Biomedical Inst MEDIATORS OF RNA INTERFERENCE THAT ARE RNA SEQUENCE SPECIFIC
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
AU2001265252A1 (en) * 2000-05-31 2001-12-11 The Johns-Hopkins University Biologically useful polyphosphates
US6325144B1 (en) * 2000-06-09 2001-12-04 Baker Hughes, Inc. Inflatable packer with feed-thru conduits
US20020151004A1 (en) * 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6649138B2 (en) * 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
PT1346059E (en) * 2000-11-29 2012-06-01 Pci Biotech As Photochemical internalization for delivery of molecules into the cytosol
US6576291B2 (en) * 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
US20030044353A1 (en) * 2001-01-05 2003-03-06 Ralph Weissleder Activatable imaging probes
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
ES2304467T3 (en) * 2001-07-10 2008-10-16 North Carolina State University NANOPARTICLE RELEASE VEHICLE.
ATE556845T1 (en) * 2001-07-20 2012-05-15 Life Technologies Corp LUMINESCENT NANOPARTICLES AND THEIR PRODUCTION
WO2004033620A2 (en) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
DE60320780D1 (en) * 2002-04-22 2008-06-19 Univ Florida FUNCTIONALIZED NANOPARTICLES AND USE METHOD
AU2003276131A1 (en) * 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
US20050118102A1 (en) * 2003-04-28 2005-06-02 Intematix Corporation Spin resonance heating and/or imaging in medical applications
US20060025713A1 (en) * 2003-05-12 2006-02-02 Alex Rosengart Magnetic particle-based therapy
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20070190155A1 (en) * 2004-03-05 2007-08-16 Leary James F Molecular programming of nanoparticle systems for an ordered and controlled sequence of events for gene-drug delivery
US20050251234A1 (en) * 2004-05-07 2005-11-10 John Kanzius Systems and methods for RF-induced hyperthermia using biological cells and nanoparticles as RF enhancer carriers
DE102005016873A1 (en) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag New nano-particle useful for production of composition to treatment and/or prophylaxis of proliferative illnesses, cancer and bacterial infections, where nano-particle is bonded therapeutic substance
US8246995B2 (en) * 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792645A (en) * 1989-03-16 1998-08-11 Boehringer Ingelheim International Gmbh Protein-polycation nucleic acid complexes and methods of use
WO1992013570A2 (en) * 1991-02-12 1992-08-20 Boehringer Ingelheim International Gmbh Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis
WO2001076633A2 (en) * 2000-04-05 2001-10-18 Qiagen Gmbh Targeted transfection of cells using a biotinylated dendrimer
WO2004108165A2 (en) * 2003-06-09 2004-12-16 Consejo Superior De Investigaciones Cientificas Magnetic nanoparticles linked to a lingand
WO2005116226A2 (en) * 2004-05-24 2005-12-08 Midatech Ltd Nanoparticles comprising rna ligands
CN101180400A (en) * 2004-05-24 2008-05-14 Mida科技有限公司 Nanoparticles comprising rna ligands
WO2006017476A2 (en) * 2004-08-02 2006-02-16 The Research Foundation Of State University Of New York Amino functionalized ormosil nanoparticles as delivery vehicles
US20060105052A1 (en) * 2004-11-15 2006-05-18 Acar Havva Y Cationic nanoparticle having an inorganic core
WO2007067733A2 (en) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAKALOVA RURNIANA ET AL: "Quantum dot-conjugated hybridization probes for preliminary screening of siRNA sequences", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 127, no. 32, August 2005 (2005-08-01), pages 11328 - 11335, XP002520110, ISSN: 0002-7863 *
CHEN ALICE A ET AL: "Quantum dots to monitor RNAi delivery and improve gene silencing -", NUCLEIC ACIDS RESEARCH, vol. 33, no. 22, 2005, pages E190, XP002520109, ISSN: 0305-1048 *
COTTEN M ET AL: "TRANSFERRIN-POLYCATION-MEDIATED INTRODUCTION OF DNA INTO HUMAN LEUKEMIC CELLS: STIMULATION BY AGENTS THAT AFFECT THE SURVIVAL OF TRANSFECTED DNA OR MODULATE TRANSFERRING RECEPTOR LEVELS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 87, 1 June 1990 (1990-06-01), pages 4033 - 4037, XP000619579, ISSN: 0027-8424 *
TAN ET AL: "Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference", BIOMATERIALS, vol. 28, no. 8, 4 January 2007 (2007-01-04), pages 1565 - 1571, XP005821955, ISSN: 0142-9612 *
WAGNER E ET AL: "COUPLING OF ADENOVIRUS TO TRANSFERRIN-POLYLYSINE/DNA COMPLEXES GREATLY ENHANCES RECEPTOR-MEDIATED GENE DELIVERY AND EXPRESSION OF TRANSFECTED GENES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 89, no. 13, 1 July 1992 (1992-07-01), pages 6099 - 6103, XP000561198, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP2099496A2 (en) 2009-09-16
AU2007333225B2 (en) 2014-06-12
WO2008073856A2 (en) 2008-06-19
CA2671850A1 (en) 2008-06-19
US20090093551A1 (en) 2009-04-09
AU2007333225A1 (en) 2008-06-19
US20080213377A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
WO2008073856A3 (en) Delivery of nanoparticles and/or agents to cells
WO2010059253A3 (en) Methods and compositions for localized agent delivery
WO2008105773A3 (en) System for targeted delivery of therapeutic agents
WO2006054240A3 (en) Ultrasound contrast agents for molecular imaging
MX341332B (en) Biodegradable lipids for the delivery of active agents.
WO2010057150A8 (en) Releasable polymeric lipids for nucleic acids delivery system
WO2011133925A3 (en) Targeted and light-activated cytosolic drug delivery
NZ596876A (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
WO2007109244A3 (en) Novel nanoparticles for delivery of active agents
WO2010132879A3 (en) Multicomponent degradable cationic polymers
WO2008030883A3 (en) Treatment of cancer
WO2009102467A3 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2008013785A3 (en) Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
WO2007118245A3 (en) Methods and compositions related to adenoassociated virus-phage particles
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2008151022A3 (en) Nucleic acid nanoparticles and uses therefor
WO2008022309A3 (en) Polyconjugates for in vivo delivery of polynucleotides
WO2007116954A3 (en) Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
WO2008060575A3 (en) Drug delivery system and method
WO2008021234A3 (en) Methods and compositions for needleless delivery of particles
WO2009134866A3 (en) Cell membrane engineering
WO2008085556A3 (en) Surfactant-free nanoparticles for drug delivery
WO2008103920A3 (en) Targeted protein cages
WO2010131907A3 (en) Sirna delivery system using self-assembled polymeric nanoparticles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869062

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009540510

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2671850

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007333225

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2007869062

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007869062

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007333225

Country of ref document: AU

Date of ref document: 20071207

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: JP